<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574170</url>
  </required_header>
  <id_info>
    <org_study_id>11 SEIN 07</org_study_id>
    <nct_id>NCT01574170</nct_id>
  </id_info>
  <brief_title>Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival</brief_title>
  <acronym>METAL3</acronym>
  <official_title>Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomedical study of interventional type. The trial will include 270 patients (180&#xD;
      patients in the first cohort and 90 patients in a second cohort) over a period of 3 years + 2&#xD;
      years of follow up.&#xD;
&#xD;
      This prospective study will be conduct in patients who will receive a third line chemotherapy&#xD;
      for metastatic breast cancer.&#xD;
&#xD;
      The main objective of the study (first cohort) is to identify patients who benefit from a&#xD;
      third line treatment in terms of overall survival with a score established from clinical,&#xD;
      histological, but also biological &quot;classic&quot; and &quot;innovative&quot; (account of circulating tumor&#xD;
      cells) criteria, all of these criteria must be measurable before the introduction of the 3rd&#xD;
      line.&#xD;
&#xD;
      This score will then be validated on the 2nd cohort.&#xD;
&#xD;
      There will be no interruption of inclusions between first and second cohort of patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 18, 2012</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival defined as the time from patient inclusion to the date of death or date of last follow-up news (censured data)</measure>
    <time_frame>11 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to progression, defined as the time from patient inclusion to the date of the first documented tumor progression</measure>
    <time_frame>11 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the EORTC QLQ-C15-PAL Questionnaire</measure>
    <time_frame>11 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction regarding therapeutic decisions at inclusion using a specific questionnaire developed by Llewellyn-Thomas</measure>
    <time_frame>11 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologists satisfaction regarding the management and communication with the patient will be studied at baseline and at the time or progression using the Likert ordinal scale</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regret or not of the patient to have followed a 3rd line of chemotherapy will be recorded at the end of the treatment using the &quot;Decision regret scale&quot; Questionnaire, established by A. O'Connor</measure>
    <time_frame>11 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluated according to the classification of NCI CTCAE (Common Terminology Criteria for Adverse Events) V4.0</measure>
    <time_frame>11 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">267</enrollment>
  <condition>Metastatic Breast Cancer Starting a Third Line Chemotherapy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Construction of a prognostic score (non-drug intervention types)</intervention_name>
    <description>Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women of more than 18 years old&#xD;
&#xD;
          2. WHO 0-4&#xD;
&#xD;
          3. Metastatic breast cancer&#xD;
&#xD;
          4. Progression after two lines of chemotherapy with treatment decision by investigator to&#xD;
             start a third-line chemotherapy&#xD;
&#xD;
          5. Evaluable disease&#xD;
&#xD;
          6. Histology: breast carcinoma whatever the histological type, grade, hormone receptor&#xD;
             expression and HER-2&#xD;
&#xD;
          7. Patient able to complete the EORTC PAL 15 Questionnaire&#xD;
&#xD;
          8. Patient member in a national insurance scheme&#xD;
&#xD;
          9. Informed consent obtained and signed by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other (s) cancer (s) potentially metastatic (s)&#xD;
&#xD;
          2. Woman participating in a third line chemotherapy clinical trial&#xD;
&#xD;
          3. Pregnant women or nursing mothers can not participate in the study&#xD;
&#xD;
          4. Patient under legal guardianship&#xD;
&#xD;
          5. Patient unable to undergo medical test for various reasons including social or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence MD DALENC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.M.C.O. Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>26609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Jean Rougier</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Castres-Mazamet</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Parc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de l'Ormeau</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique La Croix du Sud</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer,</keyword>
  <keyword>Third line metastatic</keyword>
  <keyword>Chemotherapy,</keyword>
  <keyword>Overall survival,</keyword>
  <keyword>Quality of life.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

